GDEN:NASDAQGolden Entertainment, Inc. Analysis
Data as of 2026-06-09 - not real-time
$28.55
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Golden Entertainment is trading just above its 20‑day SMA (≈28.38) and comfortably above the 50‑day SMA, indicating a short‑term bullish bias, but the MACD histogram has turned negative and the signal line is bearish, suggesting momentum may be waning. RSI sits near 60, which is still in bullish territory but approaching overbought levels, and the price is flirting with the calculated resistance around $28.85 while support sits at $27.77. The stock’s volatility of roughly 13% over the past month is moderate, and the computed beta of 0.27 points to low systematic risk, yet the casino sector carries inherent regulatory and geographic concentration risks. Fundamentally, the company reports negative profit margins, a trailing EPS of –$0.23, and a staggering debt‑to‑equity ratio above 120, making the current dividend yield of 3.5% appear unsustainable (payout ratio >400%). Moreover, the discounted cash‑flow model values the firm at just $1.48 per share, implying the market price is dramatically overvalued, though analysts’ consensus targets hover around $30, reflecting a modest upside of about 5% in the upside/downside metric. The “Extreme Greed” reading on the fear‑and‑greed index underscores market optimism that may be disconnected from the underlying financial stress.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bearish MACD signal despite bullish SMA alignment
- High debt load and negative earnings
- Dividend yield likely unsustainable
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with limited upside
- Sector’s regulatory environment remains a drag
- Valuation gap between market price and DCF fair value
Long Term
> 3 yearsCautious
Model confidence: 7/10
Key Factors
- Persistent negative profit margins and weak ROE
- Elevated debt‑to‑equity ratio threatening financial stability
- Fundamental overvaluation relative to intrinsic DCF estimate
Key Metrics & Analysis
Financial Health
Revenue Growth-5.20%
Profit Margin-0.95%
P/E Ratio23.6
ROE-1.35%
ROA1.89%
Debt/Equity123.06
P/B Ratio1.8
Op. Cash Flow$83.1M
Free Cash Flow$38.4M
Technical Analysis
TrendBullish
RSI60.7
Support$27.77
Resistance$28.85
MA 20$28.38
MA 50$27.87
MA 200$26.62
MACDBearish
VolumeIncreasing
Fear & Greed Index87.64
Valuation
Fair Value$1.48
Target Price$30.00
Upside/Downside5.08%
GradeOvervalued
TypeValue
Dividend Yield3.50%
Risk Assessment
Beta0.27
Volatility13.28%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.